Replimune Group (NASDAQ:REPL) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Replimune Group (NASDAQ:REPL) from a hold rating to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.

Several other research analysts have also issued reports on the stock. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $4.00 to $18.00 in a research report on Monday. Cantor Fitzgerald raised shares of Replimune Group from a “neutral” rating to an “overweight” rating in a research note on Wednesday, July 30th. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $3.00 to $13.00 in a research note on Monday. Piper Sandler raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a research note on Monday. Finally, Barclays downgraded shares of Replimune Group from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $17.00 to $3.00 in a research note on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $11.00.

Replimune Group Stock Up 2.5%

Shares of NASDAQ:REPL opened at $8.30 on Monday. Replimune Group has a 52-week low of $2.68 and a 52-week high of $17.00. The firm has a fifty day moving average of $5.23 and a 200 day moving average of $7.29. The firm has a market capitalization of $647.90 million, a PE ratio of -2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.94 and a current ratio of 6.94.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). As a group, research analysts anticipate that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other news, CFO Emily Luisa Hill sold 9,154 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares of the company’s stock, valued at approximately $721,556.16. This represents a 6.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of the company. Griffin Asset Management Inc. bought a new position in shares of Replimune Group during the third quarter valued at about $82,000. Osaic Holdings Inc. raised its stake in shares of Replimune Group by 26,006.0% during the second quarter. Osaic Holdings Inc. now owns 26,106 shares of the company’s stock valued at $243,000 after acquiring an additional 26,006 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of Replimune Group by 394.0% during the second quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock valued at $631,000 after acquiring an additional 54,178 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Replimune Group by 2,020.8% during the second quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock valued at $90,000 after acquiring an additional 9,235 shares during the last quarter. Finally, Exome Asset Management LLC raised its stake in shares of Replimune Group by 34.9% during the second quarter. Exome Asset Management LLC now owns 397,846 shares of the company’s stock valued at $3,696,000 after acquiring an additional 103,000 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.